AMAG Pharmaceuticals announced its Board of Directors has appointed Scott Myers as AMAG’s President and Chief Executive Officer, and member of the Board, effective immediately. Myers succeeds William Heiden, who is stepping down from such roles in light of Myers’ appointment.
“Scott is a seasoned leader with exceptional experience, skill set and passion, and it became evident to the Board through its rigorous search that Scott is the ideal candidate to lead AMAG forward,” said Gino Santini, Chairman of AMAG’s Board. “Scott’s track record of success, coupled with his experience leading companies with development stage and commercialized assets, uniquely positions him to lead the Company. The Board is confident that Scott will maximize AMAG’s strengths and proven capabilities and enable the Company to better serve patients.”
Myers brings nearly three decades of global pharmaceutical and medical technology experience to AMAG. Myers most recently served as Chairman and Chief Executive Officer of Rainier Therapeutics, a clinical-stage biotechnology company focused on metastatic bladder cancer. Prior to joining Rainier, Myers served as Chief Executive Officer, President and as a director of Cascadian Therapeutics. Myers also served as Chief Executive Officer of Aerocrine AB, a medical device company from 2011 to 2015. While at the helm of these companies, Myers drove transformation that maximized growth and delivered significant long-term value.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox! Sign up now!
“AMAG is at a pivotal point in its evolution and I look forward to working with AMAG’s Board, its leadership team and its dedicated employees to advance the strategic plan, further define the Company’s future, optimize its current products and bring innovative therapies to patients in need,” said Myers. “We have a significant opportunity ahead of us to unlock the potential of AMAG’s pipeline and leverage its existing commercial strengths to drive long-term growth and shareholder value.”
Myers is currently an independent director of Selecta Biosciences where he serves as the Chair of the Compensation and Benefits Committee, as well as a member of the Nominating and Governance Committee. Mr. Myers also serves as an independent director for Harpoon Therapeutics, a clinical stage biotechnology company where he serves on the Audit Committee. Mr. Myers began his career in management consulting and then moved into the pharmaceutical industry through senior leadership roles at Johnson & Johnson, DOV Pharmaceuticals and UCB.
Myers holds a Bachelor of Arts in Biology from Northwestern University in Evanston, Illinois, and a Master of Business Administration from The University of Chicago Graduate School of Business (Booth) in Chicago, Illinois.